These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26945298)

  • 21. The drug budget silo mentality: the Dutch case.
    Koopmanschap MA; Rutten FF
    Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending?
    Seeley E; Kesselheim AS
    Issue Brief (Commonw Fund); 2017 Sep; 2017():1-8. PubMed ID: 28953345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 27. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consequences of implementing a drug budget for office-based physicians in Germany.
    Schöffski O
    Pharmacoeconomics; 1996; 10 Suppl 2():37-47. PubMed ID: 10163434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Government Patent Use': A Legal Approach To Reducing Drug Spending.
    Kapczynski A; Kesselheim AS
    Health Aff (Millwood); 2016 May; 35(5):791-7. PubMed ID: 27140984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State Initiatives to Control Medication Costs--Can Transparency Legislation Help?
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2016 Jun; 374(24):2301-4. PubMed ID: 27305189
    [No Abstract]   [Full Text] [Related]  

  • 32. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
    Kaiser U; Mendez SJ; Rønde T; Ullrich H
    J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.
    Wolitz RE
    J Leg Med; 2019; 39(2):177-211. PubMed ID: 31503531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is a new drug worth? An innovative model for performance-based pricing.
    Dranitsaris G; Dorward K; Owens RC; Schipper H
    Eur J Cancer Care (Engl); 2015 May; 24(3):313-20. PubMed ID: 25256668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.
    Conti R; Dusetzina SB; Sachs R
    Health Aff (Millwood); 2020 Mar; 39(3):445-452. PubMed ID: 32119622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.